Minerva Neurosciences, Inc.
NERV · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.09 | 0.07 | 0.08 | 0.01 |
| FCF Yield | -18.26% | -15.69% | 0.00% | -30.75% |
| EV / EBITDA | -1.34 | 0.68 | 1.18 | 1.07 |
| Quality | ||||
| ROIC | -11.19% | -12.10% | -12.65% | -13.18% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.06 | 0.63 | 1.21 | -0.19 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -42.80% | 0.00% | 0.00% | -18.72% |
| Safety | ||||
| Net Debt / EBITDA | 4.48 | 4.68 | 4.61 | 5.00 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -62,457.22 | 0.00 | 0.00 | 0.00 |